Opinion

Video

ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone

Author(s):

Alfred L. Garfall, MD

Alfred L. Garfall, MD, discusses follow-up data from the DREAMM-8 study presented at ASCO 2024.

Video content above is prompted by the following questions:

  1. Discuss the data presented at ASCO 2024 on the DREAMM-8 study (NCT04484623) of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed/refractory multiple myeloma (RRMM). (Abstract)
    1. What was the objective of this study?
    2. How was this study designed/what methodology was used?
    3. What results were presented?
      1. N=155
      2. Median follow-up: 21.78 months
      3. PFS
      4. ORR
      5. Median duration of response
      6. OS
      7. Safety
  2. Please provide your key takeaways from this study.How might these findings impact the management of patients with RRMM?
  3. Belantamab mafodotin was previously withdrawn from the US market for RRMM following results from the phase 3 DREAMM-3 trial (NCT04162210) which did not meet its primary endpoint of progression-free survival (PFS). How do the results of the DREAMM-8 trial shed light on potential advantages of BPd in patients with RRMM?
Related Videos
Leland Metheny, MD, University Hospitals Seidman Cancer Center
Jason Porter, MD, an expert on lung cancer
1 KOL is featured in this program.
1 KOL is featured in this program.
Joseph Mikhael, MD, an expert on multiple myeloma
Jason Porter, MD, an expert on lung cancer
Jason Porter, MD, an expert on lung cancer
Joseph Mikhael, MD, an expert on multiple myeloma
Alfred L. Garfall, MD, an expert on multiple myeloma
Joseph Mikhael, MD, an expert on multiple myeloma
Related Content
Leland Metheny, MD, University Hospitals Seidman Cancer Center
August 30th 2024

Triple-Target CAR T Cells: Benefits and Challenges

Maggie L. Shaw
In part 1 of our interview with Leland Metheny, MD, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma.
Regeneron logo | Image credit: Casimiro – stock.adobe.com
August 21st 2024

FDA Issues CRL for Linvoseltamab in R/R Multiple Myeloma

Hayden E. Klein
The complete response letter (CRL) was issued based on a pre-approval inspection at a third-party fill/finish manufacturer.
stem cells | Image Credit: jarun011-stock.adobe.com
August 20th 2024

Second ASCT Extends Survival in Relapsed Multiple Myeloma

Maggie L. Shaw
To continue the response they experienced with a first autologous stem‐cell transplant (ASCT) for their multiple myeloma, patients in this analysis received a second ASCT, with French investigators evaluating their outcomes.
MM treatment | Image Credit: Dzmitry-stock.adobe.com
August 14th 2024

Challenges With Pomalidomide for Patients With Comorbid RRMM, CKD

Maggie L. Shaw
Patients who have comorbid relapsed/refractory multiple myeloma (RRMM) and advanced chronic kidney disease (CKD) are often excluded from clinical trials, leaving treatment gaps for these high-risk patients.
MM blood test | Image Credit: luchschenF-stock.adobe.com
August 6th 2024

Novel Therapies Needed for Older Patients With RRMM

Maggie L. Shaw
Relapsed/refractory multiple myeloma (RRMM) remains an incurable hematologic cancer, often resulting in patients treated with several classes of medications—particularly older patients.
FDA | Image Credit: ra2studio-stock.adobe.com
July 31st 2024

Daratumumab and Hyaluronidase-fihj–Based Quadruplet Regimen Approved in MM

Maggie L. Shaw
Daratumumab/hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone is now approved by the FDA to treat newly diagnosed multiple myeloma (MM) in patients eligible for autologous stem cell transplant.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo